期刊文献+

白细胞介素33/转硫酶同系物2信号通路与皮肤相关性疾病的研究进展 被引量:1

Interleukin- 33/sulfurtransferase homolog 2 signaling pathway and related skin diseases
原文传递
导出
摘要 白细胞介素33/转硫酶同系物2信号通路是一条促炎症通路,通过增加T淋巴细胞介导的炎症反应刺激Th2细胞因子的分泌,促进肥大细胞和嗜酸性粒细胞脱颗粒,及诱导Th2细胞和中性粒细胞趋化,在银屑病、白癜风、特应性皮炎和鳞状细胞癌等多种皮肤炎症性疾病的免疫反应和肿瘤的免疫应答中发挥作用。研究表明,转硫酶同系物2基因存在单核苷酸多态性及编码变异,因此,白细胞介素33/转硫酶同系物2通路在疾病的发病机制中也表现了一定的遗传背景。转硫酶同系物2基因多态性可能提高了患者的患病风险。免疫组化可以指导治疗方案的选择和预后的判断,而白细胞介素33和(或)转硫酶同系物2水平的降低则有利于炎症性疾病的治疗。 Intedeukin-33 (IL-33)/sulfurtransferase homolog 2 (ST2) signaling pathway, a pro- inflammatory pathway, plays an important role in immune reactions in multiple inflammatory skin diseases (such as psoriasis, vitiligo and atopie dermatitis) and tumors (such as squamous cell carcinoma) by enhancing T lymphocyte-mediated inflammatory reactions, stimulating secretion of T helper type 2 (Th2) eytokines, promoting degranulation of mast cells and eosinophils, and inducing chemotaxis of Th2 cells and neutrophils. Studies have indicated single nucleotide polymorphisms (SNPs) and encoding variability of the ST2 gene, which may contribute to the genetic background of the IL- 33/ST2 signaling pathway in the pathogenesis of diseases. ST2 gene polymorphisms may increase the risk of diseases in patients. Immunohistoehemical study may be used to guide the choice of treatment protocols and judgment of prognoses. Moreover, the decrease in IL-33 and/or ST2 levels is beneficial to the treatment of inflammatory diseases.
出处 《国际皮肤性病学杂志》 2017年第1期47-49,共3页 International Journal of Dermatology and Venereology
关键词 白细胞介素33 白癜风 银屑病 皮炎 特应性 皮肤肿瘤 转硫酶同系物2信号通路 Interleukin-33 Vitiligo Psoriasis Dermatitis, atopie Skin neoplasms ST2 signaling pathway
  • 相关文献

参考文献3

二级参考文献54

  • 1Lili Y, Yi W, Ji Y, et al. Global activation of CD8+ cytotoxic Tlymphocytes correlates with an impairment in regulatory T cellsin patients with generalized vitiligo. PLoS One, 2012, 7(5):e37513.
  • 2Pichler R, Sfetsos K, Badics B, et al. Lymphocyte imbalancein vitiligo patients indicated by elevated CD4+/CD8 + T-cellratio. Wien Med Wochenschr, 2009, 159(13-14): 337-341.
  • 3Lee AY. Role of keratinocytes in the development of vitiligo.Ann Dermatol, 2012,24(2): 115-125.
  • 4Singh S, Singh U, Pandey SS. Serum concentration of IL-6, IL-2,TNF-a, and IFN7 in Vitiligo patients. Indian J Dermatol,2012,57(1): 12-14.
  • 5Galadari I. Serum levels of the soluble interleukin-2 receptorin vitiligo patients in UAE. Eur Ann Allergy Clin Immunol,2005,37(3): 109-111.
  • 6Yeo UC, Yang YS, Park KB, et al. Serum concentration of thesoluble interleukin-2 receptor in vitiligo patients. J DermatolSci, 1999’ 19(3): 182-188.
  • 7van den Boom JG, Konijnenberg D, Dellemijn TA, et al.Autoimmune destruction of skin melanocytes by perilesionalT cells from vitiligo patients. J Invest Dermatol,2009,129(9): 2220-2232.
  • 8Steitz J, Wenzel J, Gaffal E, et al. Initiation and regulation ofCD8+ T cells recognizing melanocytic antigens in the epidermis:implications for the pathophysiology of vitiligo. Eur J Cell Biol,2004, 83(11-12): 797-803.
  • 9Jeong YM, Choi YG, Kim DS, et al. Cytoprotective effect ofgreen tea extract and quercetin against hydrogen peroxide -induced oxidative stress. Arch Pharm Res, 2005,28 ( 11 ):1251-1256.
  • 10Jalel A, Soumaya GS, Hamdaoui MH. Vitiligo treatment withvitamins, minerals and polyphenol supplementation. Indian JDermatol, 2009, 54(4): 357-360.

共引文献36

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部